In just three months, Phlow and Enveda generated and analyzed nearly 20,000 unique reactions, creating one of the largest high-quality datasets of its kind. The resulting uniform dataset is ...
Enveda has been using AI to power its drug discovery platform for several years. The company injected $230 million into ...
Strong R&D investment, advanced manufacturing technologies, and supportive government policies accelerate global API production growth.Austin, Texas, Jan. 15, 2026 (GLOBE NEWSWIRE) -- Small Molecule ...
The "Understanding Active Pharmaceutical Ingredients (APIs) Training Course (Apr 29th - Apr 30th, 2026)" training has been added to ResearchAndMarkets.com's offering. An active pharmaceutical ...
PharmTech recently spoke with Saharsh Davuluri, Vice Chairman and Managing Director, Neuland Labs, to get his perspective on trends that shaped pharmaceutical development and manufacturing in 2025 and ...
After several notable moves to grow the reach of its biomanufacturing platform in recent months, Antheia is linking arms with a pharmaceutical ingredient juggernaut in this field. Antheia is teaming ...
Even when a drug finishes its production in the U.S., its active and inactive components often come from overseas. While pharmaceutical companies have been unveiling plans for new U.S. manufacturing ...
This investment comes as LGM Pharma experiences sustained growth in prescription drug projects, including 505(b)(2) and Abbreviated New Drug Application (ANDA) programs. The Rosenberg facility ...
Market valued at $72.4M in 2024, projected 7.30% CAGR growth driven by pharmaceutical API synthesis, food-grade ...
Despite receiving a prior wrist slap from the FDA in the shape of a Form 483, Sanofi is still working to right the ship at a U.S. drug ingredients plant tied to its longstanding subsidiary Genzyme.
BOCA RATON, Fla.--(BUSINESS WIRE)--LGM Pharma, a leading provider of tailored API and CDMO services for the full drug product lifecycle, today announced an investment of over $6 million to expand its ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results